PD-1 /PD-L1 checkpoint in hematological malignancies

Leuk Res. 2018 Apr:67:45-55. doi: 10.1016/j.leukres.2018.01.014. Epub 2018 Jan 31.

Abstract

Programmed cell death protein 1 (PD-1), is a cell surface receptor with an important role in down-regulating the immune system and promoting self-tolerance by suppressing T cell inflammatory activity. PD-1/PDL1 axis represents a checkpoint to control immune responses and it is often used as a mechanism of immune escaping by cancers and infectious diseases. Many data demonstrate its important role in solid tumors and report emerging evidences in lymphoproliferative disorders. In this review, we summarized the available data on the role of PD-1/PD-L1 checkpoint in lymphoproliferative diseases and the therapeutics use of monoclonal blocking antibodies.

Keywords: Immunotherapy; Lymphoproliferative disorders; PD-1; PD-1/PD-L1 checkpoint; PD-L1.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • B7-H1 Antigen / immunology
  • B7-H1 Antigen / physiology*
  • Hematologic Neoplasms / immunology*
  • Hematologic Neoplasms / therapy
  • Hodgkin Disease / immunology
  • Hodgkin Disease / therapy
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy
  • Lymphoma, Non-Hodgkin / immunology
  • Lymphoma, Non-Hodgkin / therapy
  • Programmed Cell Death 1 Receptor / immunology
  • Programmed Cell Death 1 Receptor / physiology*
  • Tumor Escape

Substances

  • Antibodies, Monoclonal
  • B7-H1 Antigen
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor